2023 Expertise Partners
Expertise Partner: GemPharmatech
GemPharmatech Co. Ltd. is a leading company in China to provide high-quality animal model resources and services for biomedical community as well as pharmaceutical companies. Based on more than 16 years’ practice in laboratory animals of the former entity, GemPharmatech has the vision and is striving to become one of the best one-stop service center for production, distribution, and phenotyping of gene-modified mouse models for partners all across the world.
Expertise Partner: genOway
For the past 20 years, genOway has aimed to improve the predictability and reliability of preclinical data by designing models of high physiological relevancy to best meet researchers’ needs. With a catalog of humanized immune checkpoint mouse models, and mice featuring the human immune system, genOway possesses a broad set of tools to help decipher the mechanism of action as well as the efficacy and safety of drugs targeting the immune system. Additionally, genOway owns strong intellectual property rights, combining patents and licensing agreements, enabling the company to provide end users the necessary freedom to operate.
Expertise Partner: Labcorp
Labcorp Oncology is committed to advancing cancer care by pioneering scientific breakthroughs, powering better decisions through actionable data-driven patient insights and bringing healthcare within reach for all cancer patients throughout their continuum of
care. With our comprehensive, specialized diagnostic services and our drug development capabilities, Labcorp is uniquely positioned to support you, from discovery through post-marketing and commercialization— using a biomarker-driven strategy throughout the entire
process.
Expertise Partner: Certis Oncology Solutions
Certis Oncology Solutions is a life science technology company committed to realizing the promise of precision oncology. Our product is “Oncology Intelligence™”— highly predictive therapeutic response data derived from advanced biological models of cancer. Our proprietary platform informs individual treatment decisions and accelerates the development of new cancer therapies. We partner with therapeutics developers to help close the problematic translation gap between preclinical studies and clinical trials. Through more clinically relevant, well-characterized and annotated models, advanced imaging technology and thoughtfully designed studies, Certis brings greater certainty to go/no-go development decisions.
2023 Innovation Partners
Innovation Partner: Reaction Biology
Our clients are seeking answers in their quest to discover effective treatments for patients. Finding these answers is our mission as a CRO. Our method is to accelerate the drug discovery process with the widest possible range of assays and services but also to maintain an integrated view of the journey to a lead drug candidate. We strive to provide excellent data, delivered in a timely, collaborative manner by outstanding scientists. Who are we? We’re your partner.
Innovation Partner: BioReperia
BioReperia offers the next-generation in-vivo platform. In 5 days, we provide highly translational efficacy data on both tumor regression as well as metastasis dissemination. The platform includes efficacy testing in both CDX, PDX, and primary tumors from patients and accommodate all types of compounds from small molecules to large peptides, antibodies, and ADCs, as well as immuno-therapies. The platform is also CE certified as a tool for precision medicine.
2023 Spotlight Partner
Spotlight Partner: Lide Biotech
LIDE is an award-winning oncology contract research organization with 12 years of delivering drug evaluation services to 200+ clients worldwide. We offer traditional preclinical CRO services like pharmacology, PK, and biomarker studies with 70+ CDX models and 2000 patient-derived xenograft (PDX) models. Our library covers 50+ cancer types and 200+ models harbor special naturally-occurred drug-resistant and/or genetic alterations. Ask us about our proprietary tools for in-vivo drug validation in 7-10 days.
2023 Exhibition Partners
Exhibition Partner: Champions Oncology
At Champions Oncology, we are passionate about aiding the pharmaceutical industry in
developing the innovative treatments of today and the cures for tomorrow. We provide end-to-end research and development solutions throughout the drug development lifecycle. From
screens using commercially-available and custom cell lines, to studies leveraging syngeneic or traditional patient-derived studies xenograft (PDX) models, and modeling treatment response in the clinic, Champions Oncology is your partner in meeting today’s needs and innovating for tomorrow’s challenges.
Exhibition Partner: ChemPartner
ChemPartner is a CRO provider with 20 years of experience supporting drug discovery and development from concept to IND, with a focus on oncology, immunology, and CNS disease. Our oncology team offers >2,000 biochemistry assays, >800 cancer cell lines for screening and functional assays, >300 CDX and >50 syngeneic models at both subcutaneous and orthotopic settings, as well as >500 PDX. Additionally, ChemPartner has a fully equipped suite of ex vivo capabilities, such as flow, MSD, and IHC
Exhibition Partner: EPO
EPO, founded in Berlin-Buch in 1997, specializes in preclinical oncology services. With 600+ well-characterized PDX models, corresponding primary cell lines and humanized models, we provide services to 450+ global customers. Our highly qualified team ensures quick responses, flexible study designs, and transparent communication. Actively involved in several research consortia, EPO contributes to scientific publications and conferences. Driven by science and dedicated to service, we are offering tailored solutions for developing novel anti-cancer drugs.
Exhibition Partner: WuXi AppTec
WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the pharmaceutical and healthcare industry around the world to advance discoveries and deliver groundbreaking treatments to patients.
WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions.
2023 Event Partner
Event Partner: Crown Bioscience
Crown Bioscience is a cutting-edge translational technology company providing drug discovery and preclinical development services in the areas of oncology, immunology, inflammation, cardiovascular, and metabolic disease. We bring clarity to drug discovery and enable clients around the world to deliver superior clinical candidates. Our premier translational platforms for cancer, inflammation, and metabolic disease help our clients accelerate their new drug development programs.